Genomic Health Company Profile (NASDAQ:GHDX)

About Genomic Health

Genomic Health logoGenomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GHDX
  • CUSIP: 37244C10
Key Metrics:
  • Previous Close: $29.11
  • 50 Day Moving Average: $28.28
  • 200 Day Moving Average: $29.14
  • 52-Week Range: $33,629,000.00 - $22.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 83.17
  • P/E Growth: 176.42
  • Market Cap: $978.94M
  • Outstanding Shares: 33,629,000
  • Beta: 0.46
  • Net Margins: -5.77%
  • Return on Equity: -14.13%
  • Return on Assets: -10.77%
  • Current Ratio: 3.28%
  • Quick Ratio: 3.28%
Additional Links:
Companies Related to Genomic Health:

Analyst Ratings

Consensus Ratings for Genomic Health (NASDAQ:GHDX) (?)
Ratings Breakdown: 2 Sell Ratings, 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $30.83 (5.92% upside)

Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
DateFirmActionRatingPrice TargetDetails
1/23/2017Canaccord GenuitySet Price TargetBuy$38.00View Rating Details
1/18/2017Deutsche Bank AGReiterated RatingHold$31.00View Rating Details
1/9/2017Barclays PLCReiterated RatingSell$27.00View Rating Details
1/4/2017Cowen and CompanyDowngradeOutperform -> Market Perform$35.00 -> $34.00View Rating Details
8/17/2016Jefferies Group LLCBoost Price TargetHold$25.00 -> $27.00View Rating Details
8/3/2016Bank of America CorpSet Price TargetSell$28.00View Rating Details
6/21/2016Leerink SwannReiterated RatingBuyView Rating Details
2/11/2016Piper Jaffray CompaniesReiterated RatingIn-Line$32.00 -> $31.00View Rating Details
11/4/2015Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$29.00View Rating Details
11/2/2015JMP SecuritiesBoost Price TargetOutperform$34.00 -> $36.00View Rating Details
5/28/2015Credit Suisse GroupReiterated RatingNeutralView Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Genomic Health (NASDAQ:GHDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q416($0.01)$0.04$84.08 million$82.70 millionViewListenView Earnings Details
11/1/2016Q316($0.09)($0.08)$83.24 million$82.30 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.26)($0.30)$68.20 millionViewN/AView Earnings Details
2/10/2015Q414($0.22)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/5/2014Q214($0.26)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Genomic Health (NASDAQ:GHDX)
Current Year EPS Consensus Estimate: $0.05 EPS
Next Year EPS Consensus Estimate: $0.35 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.25)($0.07)($0.17)
Q2 20167($0.20)($0.01)($0.11)
Q3 20164($0.15)($0.01)($0.08)
Q4 20165($0.02)$0.02$0.00
Q1 20172$0.01$0.02$0.02
Q2 20172$0.01$0.04$0.03
Q3 20172$0.01$0.03$0.02
Q4 20172$0.01$0.09$0.05
(Data provided by Zacks Investment Research)


Dividend History for Genomic Health (NASDAQ:GHDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Genomic Health (NASDAQ:GHDX)
Insider Ownership Percentage: 47.00%
Institutional Ownership Percentage: 89.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Phillip G. FebboinsiderSell2,495$30.09$75,074.55View SEC Filing  
1/23/2017Steven ShakInsiderSell5,000$27.28$136,400.00View SEC Filing  
1/10/2017G Bradley ColeCOOSell5,000$29.22$146,100.00View SEC Filing  
12/5/2016Kimberly J PopovitsInsiderSell5,000$30.02$150,100.00View SEC Filing  
11/3/2016Kimberly J PopovitsInsiderSell5,313$28.88$153,439.44View SEC Filing  
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.10View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.00View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.00View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Genomic Health (NASDAQ:GHDX)
DateHeadline logoGenomic Health : tops 4Q profit forecasts (NASDAQ:GHDX) - February 16 at 5:21 PM logoEdited Transcript of GHDX earnings conference call or presentation 14-Feb-17 9:30pm GMT (NASDAQ:GHDX) - February 16 at 5:21 PM logoGenomic Health, Inc. Swings to a Profit (NASDAQ:GHDX) - February 16 at 5:21 PM logoWhy Genomic Health Inc. Jumped Higher Today (NASDAQ:GHDX) - February 16 at 5:21 PM logoFour New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection (NASDAQ:GHDX) - February 16 at 5:21 PM logoGenomic Health, Inc. :GHDX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 (NASDAQ:GHDX) - February 16 at 5:21 PM logoEagleClaw Capital Managment, LLC Buys Silver Wheaton, Magellan Midstream Partners LP, Vanguard ... (NASDAQ:GHDX) - February 14 at 6:32 PM logoQ4 2016 Genomic Health Inc Earnings Release - After Market Close (NASDAQ:GHDX) - February 14 at 6:32 PM logoGenomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook (NASDAQ:GHDX) - February 14 at 6:32 PM logoGENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi (NASDAQ:GHDX) - February 14 at 6:32 PM logoGenomic Health tops 4Q profit forecasts (NASDAQ:GHDX) - February 14 at 6:32 PM logoGenomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017 (NASDAQ:GHDX) - February 7 at 6:42 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Genomic Health, Inc. (NASDAQ:GHDX) - Wall Street Beacon (NASDAQ:GHDX) - January 22 at 5:19 PM
News IconEarnings Analysis & Update for Genomic Health, Inc. (NASDAQ:GHDX)? - Aiken Advocate (NASDAQ:GHDX) - January 21 at 4:46 AM logoDeutsche Bank Starts Genomic Health Inc. (GHDX) at Hold - (NASDAQ:GHDX) - January 18 at 10:51 PM logoCoverage initiated on Genomic Health by Deutsche Bank (NASDAQ:GHDX) - January 18 at 5:49 PM
News IconWill The Needle Move For Genomic Health, Inc. (NASDAQ:GHDX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:GHDX) - January 17 at 8:39 AM
News IconGenomic Health, Inc. (GHDX) stock falls, "Sell" rating reaffirmed by Barclays PLC Analysts - BNB Daily (blog) (NASDAQ:GHDX) - January 11 at 3:32 PM
News IconGenomic Health Inc GHDX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:GHDX) - January 7 at 11:50 PM logoGenomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference - PR Newswire (press release) (NASDAQ:GHDX) - January 3 at 7:46 PM logoGenomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:GHDX) - January 3 at 12:04 PM logoSentiments And Ratings Alert: Genomic Health, Inc. (NASDAQ:GHDX) - Investor Newswire (NASDAQ:GHDX) - December 27 at 11:23 AM
News IconGenomic Health Announces Inclusion of Oncotype DX in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging (NASDAQ:GHDX) - December 23 at 5:39 PM logoGenomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on … (NASDAQ:GHDX) - December 22 at 5:37 PM logo8:00 am Genomic Health announces inclusion of oncotype DX in the 8th edition of American Joint Committee on Cancer criteria for breast cancer staging (NASDAQ:GHDX) - December 22 at 5:37 PM logoGenomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging (NASDAQ:GHDX) - December 22 at 5:37 PM
News IconLooking at the Numbers for Genomic Health, Inc. (NASDAQ:GHDX) - Wall Street Beacon (NASDAQ:GHDX) - December 21 at 11:23 PM
News IconWhat The Charts Are Saying About Genomic Health, Inc. (NASDAQ:GHDX) - Marion Business Daily (NASDAQ:GHDX) - December 20 at 10:35 AM logoGenomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : December 20, 2016 (NASDAQ:GHDX) - December 20 at 10:35 AM
News IconUpdate on Valuation Formula's For Genomic Health, Inc. (NASDAQ:GHDX) - The Business Journal (NASDAQ:GHDX) - December 18 at 3:43 AM logoGENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:GHDX) - December 15 at 5:59 PM logoIs Genomic Health, Inc. (GHDX) A Good Stock To Buy? - Insider Monkey (blog) (NASDAQ:GHDX) - December 15 at 4:07 AM
News IconIs Genomic Health, Inc. (GHDX) A Good Stock To Buy? (NASDAQ:GHDX) - December 15 at 12:06 AM
News IconValue Composite Score Update on Genomic Health, Inc. (NASDAQ:GHDX) - Marion Business Daily (NASDAQ:GHDX) - December 14 at 11:04 PM
News IconStock Spotlight: Zooming in on Shares of Genomic Health, Inc. (NASDAQ:GHDX) - The Business Journal (NASDAQ:GHDX) - December 14 at 4:02 AM
News IconTrading Views: Checking the Numbers for Genomic Health Inc. (GHDX) - StockTalk Daily (NASDAQ:GHDX) - December 14 at 4:02 AM
News IconReviewing the Numbers for Genomic Health, Inc. (NASDAQ:GHDX) - Business Daily Leader (NASDAQ:GHDX) - December 12 at 10:35 PM logoGenomic Health Posts Impressive Data for Oncotype DX Test (NASDAQ:GHDX) - December 12 at 11:28 AM logoGenomic Health (GHDX) Reports Results from Multiple Oncotype DX Studies (NASDAQ:GHDX) - December 11 at 10:45 AM logoGenomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering … (NASDAQ:GHDX) - December 9 at 5:39 PM
News IconGenomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine... (NASDAQ:GHDX) - December 9 at 5:39 PM logoGenomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World (NASDAQ:GHDX) - December 9 at 5:39 PM logo8:41 am Genomic Health announces results from multiple studies on Oncotype DX test in individualizing breast cancer, data includes new results from the SEER Registry program of the NCI (NASDAQ:GHDX) - December 9 at 5:39 PM logoMyriad's breast cancer test beats Genomic Health's in head-to-head study (NASDAQ:GHDX) - December 9 at 10:48 AM logoGenomic Health (GHDX) Reports Results from Multiple Oncotype DX Studies - (NASDAQ:GHDX) - December 9 at 10:25 AM
News IconLevels in Review for Genomic Health, Inc. (NASDAQ:GHDX) - The Business Journal (NASDAQ:GHDX) - December 8 at 11:05 PM logoBreast Cancer Index(SM) Predicted Patients at High Risk of Recurrence Despite Low Risk Clinical Features, New Data Suggest (NASDAQ:GHDX) - December 8 at 11:08 AM
News IconPresident and CEO of Genomic Health (NASDAQ:GHDX), Popovits Kimberly J, sells 5,000 shares worth $150,100 (NASDAQ:GHDX) - December 8 at 11:08 AM
News IconChart Indicators in Focus for Genomic Health Inc. (GHDX) - StockTalk Daily (NASDAQ:GHDX) - December 7 at 10:37 PM logoGenomic Health: Cancer Test Business Strong, Q3 Dismal (NASDAQ:GHDX) - December 7 at 10:42 AM


What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

Where is Genomic Health's stock going? Where will Genomic Health's stock price be in 2017?

7 equities research analysts have issued 12 month target prices for Genomic Health's shares. Their predictions range from $27.00 to $38.00. On average, they anticipate Genomic Health's stock price to reach $30.83 in the next year.

When will Genomic Health announce their earnings?

Genomic Health is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

Who owns Genomic Health stock?

Genomic Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Columbia Wanger Asset Management LLC (3.81%), Renaissance Technologies LLC (1.72%), State Street Corp (1.63%), Loomis Sayles & Co. L P (1.59%), FMR LLC (0.79%) and Two Sigma Investments LP (0.61%). Company insiders that own Genomic Health stock include Felix Baker, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Phillip G Febbo, Randall S Livingston and Steven Shak.

Who sold Genomic Health stock? Who is selling Genomic Health stock?

Genomic Health's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Loomis Sayles & Co. L P, GSA Capital Partners LLP, Two Sigma Investments LP, AQR Capital Management LLC and Envestnet Asset Management Inc.. Company insiders that have sold Genomic Health stock in the last year include G Bradley Cole, James J Vaughn, Kimberly J Popovits, Phillip G Febbo and Steven Shak.

Who bought Genomic Health stock? Who is buying Genomic Health stock?

Genomic Health's stock was acquired by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, State Street Corp, Bogle Investment Management L P DE, Renaissance Technologies LLC, A.R.T. Advisors LLC, Aveo Capital Partners LLC, Russell Investments Group Ltd. and Capstone Investment Advisors LLC.

How do I buy Genomic Health stock?

Shares of Genomic Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Genomic Health stock cost?

One share of Genomic Health stock can currently be purchased for approximately $29.11.

Genomic Health (NASDAQ:GHDX) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Earnings History Chart

Earnings by Quarter for Genomic Health (NASDAQ:GHDX)

Dividend History Chart

Dividend Payments by Quarter for Genomic Health (NASDAQ:GHDX)

Last Updated on 2/19/2017 by Staff